

Remarks

The claims have been amended to overcome the rejection for indefiniteness by canceling claim 1. Applicants traverse the rejections of the present claims for obviousness and contend that the claims are not obvious for the following reasons.

US Patent No. 5,753,228 teaches a process for the production of egg yolk anti bodies binding to any parasitic antigen (i.e antigen from living organism) where as the current claim relates to antibodies against the organo chlorine chemicals. Similarly the present invention differs from the teachings of the prior art, as the present invention relates to the hapten protein conjugates and not about adjuvants. As it is understood that adjuvants are useful for the slow release of the vaccine whereas the haptens are high molecular weight molecules which aid the antigen being quickly recognized by the immune system. Beasley relates to the production of polyclonal antibody against HCH by immunizing rabbits, t type of mammal, whereas the pending claim relates to avians. It is accepted by those of skill in the art that every genus of animal has a unique immune system. The present invention also has a clear advantage over Beasley et al as the production rate and effectiveness of the antibodies from the host is very high when compared to the rabbits as used by Beasley at al.

Applicants further wish to emphasize that the process of the production of the egg yolk antibodies defined briefly in the claim 6 differs from the teachings of the prior art, as the harvesting of the same is carried out in the process not taught in the prior art. Moreover, in the claimed invention, claim 8 differs from the combined teachings of the reference, that the process of production of egg yolk antibodies to small organo chlorine pesticides where in the lipid content from the egg yolk is precipitated twice to yield 75% from supernatant against the teaching of prior art. Claim 9 further differs from the combined references, that the process for the production of egg yolk antibodies to small organo chlorine compounds by haptens, whereas the prior art deals with the antibody production against the parasites or parasitic antigens from rabbits.

Therefore, applicants submit the obviousness rejections of record are improper and respectfully request withdrawal of these rejections.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Respectfully submitted,

Date August 11, 2006

FOLEY & LARDNER LLP
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5300
Facsimile: (202) 672-5399



Matthew E. Mulkeen
Registration No. 44,250